

英文原著（2020年以降）

1. Ishida T, Kimura H, Ozaki S, Kubo K, Sunami K, Takezako N, Fujita H, Hayashi T, Kiguchi T, Ohashi K, Yamamoto S, Takamatsu H, Kosugi H, Ohta K, Sakai R, Handa H, Kondo S, Abe Y, Omoto E, Mitani K, Morita S, Murakami H, Shimizu K. Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma. *Ann Hematol*. 2020;99:1063-1072.
2. Sugiura I, Suzuki K, Ri M, Cou T, Takezako N, Sunami K, Ishida T, Izumi T, Ozaki S, Shumiya Y, Iida S. Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma. *Int J Hematol*. 2020;111:57-64.
3. Suzuki K, Tsukada N, Nishimura N, Nagata Y, Okazuka K, Mishima Y, Yokoyama M, Nishiwaki K, Ishida T, Yano S, Terui Y, Suzuki K: Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis. *Int J Hematol* 2020; 111, 103-111.
4. Okazuka K, Ishida T, Nashimoto J, Uto Y, Sato K, Miyazaki K, Ogura M, Yoshiki Y, Abe Y, Tsukada N, Suzuki K: The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. *Eur J Haematol* 2020;104:110-115.
5. Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara S, Kimura S, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Matsumoto K, Aotsuka N, Gotoh M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S, Kanto Study Group for Cell, Therapy. Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis. *Biol Blood Marrow Transplant* 2020;26:998-1004.
6. Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, Koyama J, Sano M, Sekijima Y, Tahara N, Tsukada N, Tsujita K, Tsutsui H, Tomita T, Amano M, Endo J, Okada A, Oda S, Takashio S, Baba Y, Misumi Y, Yazaki M, Anzai T, Ando Y, Isobe M, Kimura T, Fukuda K: Japanese Circulation Society Joint Working, Group. JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis. *Circ J* 2020; 84: 1610-1671.
7. Katsuse K, Akiyama K, Ishida T, Kitayama C, Ishibashi Y, Ochi M, Kumasaka T, Takahashi K, Suzuki T, Nakamichi K, Saijo M, Hashida H. Progressive multifocal leukoencephalopathy in a patient with primary amyloid light-chain amyloidosis. *Clin Neurol Neurosurg*. 2020;192:105709.

8. Kimura K, Tsukamoto S, Miyazaki K, Kawajiri-Manako C, Ishii A, Rahmutulla B, Fukuyo M, Oshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Takeuchi M, Ohwada C, Iseki T, Matsusaka K, Sanada M, Yokote K, Kaneda A, Ishida T, Suzuki K, Nakaseko C, Sakaida E. Identification of clonal immunoglobulin λ light-chain gene rearrangements in AL amyloidosis using next-generation sequencing. *Exp Hematol.* 2021;101-102:34-41 e4.
9. Yasui H, Kobayashi M, Sato K, Kondoh K, Ishida T, Kaito Y, Tamura H, Handa H, Tsukune Y, Sasaki M, Komatsu N, Tanaka N, Tanaka J, Kizaki M, Kawamata T, Makiyama J, Yokoyama K, Imoto S, Tojo A, Imai Y. Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse. *Int J Clin Oncol.* 2021;26:2142-2150.
10. Hirano M, Imai Y, Kaito Y, Maruyama T, Sato K, Ishida T, Yamamoto J, Ito T, Futami M, Ri M, Yasui H, Denda T, Tanaka Y, Ota Y, Nojima M, Kamikubo Y, Gotoh N, Iida S, Handa H, Tojo A. Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma. *J Exp Clin Cancer Res.* 2021;40:110.
11. Iida S, Ishida T, Horimoto K, Kazama H, Kim H, Crawford B, Teshima T. Medical database analysis of Japanese multiple myeloma patients with planned stem cell transplantation (MEDALIST) - a focus on healthcare resource utilization and cost. *Int J Hematol.* 2021;113:271-278.
12. Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Miyazaki T, Aotsuka N, Gotoh M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis. *Transplant Cell Ther.* 2021;27:70.e1-70.e8.
13. Nakasone H, Kako S, Mori T, Takahashi S, Onizuka M, Fujiwara SI, Sakura T, Sakaida E, Yokota A, Aotsuka N, Hagihara M, Tsukada N, Hatta Y, Usuki K, Watanabe R, Gotoh M, Fujisawa S, Yano S, Kanamori H, Okamoto S, Kanda Y. Stopping tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemia. *Bone Marrow Transplant.* 2021;56:1402-1412.
14. Seo S, Usui Y, Matsuo K, Atsuta Y, Igarashi A, Fukuda T, Ozawa Y, Katayama Y, Yoshida S, Uchida N, Kondo T, Kako S, Tsukada N, Kato S, Onizuka M, Ichinohe T,

- Kimura F, Kanda Y, Miyamura K, Kanda J; JSHCT Donor Source Working Group. Impact of the combination of donor age and HLA disparity on the outcomes of unrelated bone marrow transplantation. *Bone Marrow Transplant.* 2021;56:2410–2422.
15. Nakasone H, Kako S, Tachibana T, Tanaka M, Onizuka M, Takahashi S, Yokota A, Fujiwara SI, Sakura T, Sakaida E, Fujisawa S, Yamazaki R, Gotoh M, Hagihara M, Aotsuka N, Tsukada N, Hatta Y, Shimizu H, Usuki K, Watanabe R, Mori T, Yano S, Kanamori H, Kanda Y. Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free Survival. *Transplant Cell Ther.* 2021; 27: 800. e1-800.e8.
 16. Sato K, Okazuka K, Ishida T, Sakamoto J, Kaneko S, Nashimoto J, Uto Y, Ogura M, Yoshiki Y, Abe Y, Maeda A, Hamazaki H, Tsukada N, Hiragohri Y, Suzuki K. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry. *Ann Hematol.* 2021; 100: 2989-2995.
 17. Tsukada N, Nishikori M, Goto H, Kanamori R, Nishina S, Seto T, Iida S. Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study. *Drugs Real World Outcomes.* 2021;9:63-78.
 18. Shimizu Y, Mizuno S, Fuchida S, Suzuki K, Tsukada N, Hangaishi A, Itagaki M, Kataoka K, Kako S, Sakaida E, Yoshioka S, Iida S, Doki N, Oyake T, Ichinohe T, Kanda Y, Atsuta Y, Takamatsu H, Working group of the Japanese Society for Transplantation, Cellular Therapy: Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine. *Cancer Sci.* 2021; 112: 5034-5045.
 19. Ozaki S, Handa H, Koiso H, Saitoh T, Sunami K, Ishida T, Suzuki K, Narita T, Iida S, Nakamura Y, Suzuki K, Nishimura N, Murakami H, Shimizu K. Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. *J Cancer Res Clin Oncol.* 2022;148:191-203.
 20. Iida S, Nakakoji M, Spanopoulos D, Okazuka K, Parulekar V, Ishida T. Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan. *Future Oncol.* 2022;18:3839-3852.
 21. Ishida T, Ito S, Tanaka J, Uchiyama M, Kawano Y, Moreau P, Martin T, Risse ML, Tada K, Suzuki K, Ishizawa K. Isatuximab plus carfilzomib and dexamethasone in

- Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study. *Jpn J Clin Oncol.* 2022;52:1446-1449.
22. Ri M, Suzuki K, Ishida T, Kuroda J, Tsukamoto T, Teshima T, Goto H, Jackson CC, Sun H, Pacaud L, Fujiwara E, Yeh TM, Hatayama T, Aida K, Sunagawa Y, Iida S. Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort. *Cancer Sci.* 2022;113:4267-4276.
23. Iida S, Ishida T, Miyamoto T, Teramukai S, Shirai H, Kanamori R, Tajima Y, Crawford B, Yi J, Teshima T. MEDical Database AnaLysis of Japanese multiple myeloma patientS with apheresis #2 (MEDALIST-2): the impact of plerixafor use on costs and healthcare resources during mobilization and stem cell transplantation. *Int J Hematol.* 2022;116:411-422.
24. Fuchida S, Kawamura K, Sunami K, Tsukada N, Fujii S, Ohkawara H, Usuki K, Wake A, Endo S, Ishiyama K, Ueda Y, Nakamura Y, Miyamoto T, Fukuda T, Ichinohe T, Atsuta Y, Takamatsu H. Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation. *Transplant Cell Ther.* 2022;28:76-82.
25. Konuma T, Ooi J, Nagayama H, Tomonari A, Tsukada N, Kato S, Kawakita T, Isobe M, Monna-Oiwa M, Tojo A, Iseki T, Takahashi S. Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies. *Ann Hematol.* 2022;101:177-189.
26. Tsumanuma R, Omoto E, Kumagai H, Katayama Y, Iwato K, Aoki G, Sato Y, Tsutsumi Y, Tsukada N, Iino M, Atsuta Y, Kodera Y, Okamoto S, Yabe H. The safety and efficacy of hematopoietic stem cell mobilization using biosimilar filgrastim in related donors. *Int J Hematol.* 2022;115: 882-889.
27. Miyamoto-Nagai Y, Mimura N, Tsukada N, Aotsuka N, Ri M, Katsuoka Y, Wakayama T, Suzuki R, Harazaki Y, Matsumoto M, Kumagai K, Miyake T, Ozaki S, Shono K, Tanaka H, Shimura A, Kuroda Y, Sunami K, Suzuki K, Yamashita T, Shimizu K, Murakami H, Abe M, Nakaseko C, Sakaida E. Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan. *EJHaem.* 2022;3:838-848.
28. Mizuno S, Takami A, Takamatsu H, Hanamura I, Shimazu Y, Hangaishi A, Tsukada N, Kako S, Kikuchi T, Ota S, Shimizu H, Iida S, Yoshioka S, Sawa M, Fukuda T, Kanda Y, Atsuta Y, Kawamura K. Autologous hematopoietic cell

- transplantation for myeloma patients with hepatitis B virus or hepatitis C virus in the era of novel agents. *Bone Marrow Transplant*. 2022;57:846-848.
29. Hatano K, Orimo K, Ogura M, Okabe S, Ishida T, Kubota A, Shimizu J, Hashida H. Development of Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes Syndrome after Conversion from Plasmacytoma of Bone to Multiple Myeloma. *Intern Med*. 2023;62:475-479.
 30. Kawano Y, Kim K, Min CK, Koh Y, Ishizawa K, Kim SH, Ito S, Tanaka J, Uchiyama M, Ishida T, Kim JS, Moreau P, Martin T, Tada K, Risse ML, Suzuki K. Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis. *Clin Lymphoma Myeloma Leuk*. 2023;23:e360-e367.
 31. San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernandez de Larrea C, Martinez-Lopez J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Orio A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Ledvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yer TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. *N Engl J Med*. 2023;389:335-347.
 32. Handa H, Ishida T, Ozaki S, Mori A, Kato K, Iida S. Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database. *PLoS One*. 2023;18:e0283931.
 33. Ishida T, Nakakoji M, Murata T, Matsuyama F, Iida S. valuating process utilities for the treatment burden of chemotherapy in multiple myeloma in Japan: a time trade-off valuation study. *J Med Econ*. 2023;26:565-573.
 34. Minakata D, Ishida T, Ando K, Suzuki R, Tanaka J, Hagiwara S, Ananthakrishnan R, Kuwayama S, Nishio M, Kanda Y, Suzuki K. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. *Int J Hematol*. 2023;117:729-737.
 35. Suzuki K, Shimazu Y, Minakata D, Ikeda T, Takahashi H, Tsukada N, Kanda Y, Doki N, Nishiwaki K, Miwa A, Sawa M, Kataoka K, Hiramoto N, Ota S, Itagaki M, Ichinohe T, Atsuta Y, Yano S, Kawamura K, Working group of the Japan Society for Transplantation Cellular, Therapy. Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis. *Transplant Cell Ther*. 2023;29:688 e1-688 e13.
 36. Okada Y, Kimura F, Kurita N, Takahashi H, Shimazu Y, Mizuno S, Uchida N,

- Kataoka K, Hiramoto N, Ota S, Kako S, Tsukada N, Kanda Y, Kurahashi S, Doki N, Nishikawa A, Kim SW, Hangaishi A, Kanda J, Fukuda T, Atsuta Y, Kondo E, Kawamura K, Nakasone, H. Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma. *Cytotherapy*. 2023;25:1212-1219.
37. Takamatsu H, Matsuda T, Mizuno S, Takahashi T, Fuchida S, Hanamura I, Kataoka K, Tsukada N, Matsumoto M, Hangaishi A, Doki N, Uchida N, Sawa M, Maruyama Y, Kurahashi S, Nagafuji K, Harazaki Y, Kako S, Iida S, Ichinohe T, Kanda Y, Atsuta Y, Sunami K, Multiple Myeloma Working Group in the Japanese Society for Transplantation Cellular, Therapy. Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs. *Haematologica*. 2023;108:3399-3408.
 38. Yanagisawa R, Hirakawa T, Doki N, Ikegame K, Matsuoka K, Fukuda T, Nakamae H, Ota S, Hiramoto N, Ishikawa J, Ara T, Tanaka M, Koga Y, Kawakita T, Maruyama Y, Kanda Y, Hino M, Atsuta Y, Yabe H, Tsukada, N. Severe short-term adverse events in related bone marrow or peripheral blood stem cell donors. *Int J Hematol*. 2023;117:421-427.
 39. Ishida T, Nakakoji M, Murata T, Matsuyama F, Iida S. Evaluating process utilities for the treatment burden of chemotherapy in multiple myeloma in Japan: a time trade-off valuation study. *J Med Econ*. 2023;26:565-573.
 40. Kikuchi T, Tsukada N, Kunisada K, Nomura-Yogo M, Oda Y, Sato K, Takei T, Ogura M, Abe Y, Suzuki K, Ishida T. Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies. *Ann Hematol*. 2023;102:3489-3497.
 38. Kikuchi T, Tsukada N, Oda Y, Nomura-Yogo M, Takei T, Sato K, Ogura M, Abe Y, Suzuki K, Ishida T. Real-World Clinical Outcomes in Patients With Multiple Myeloma Administered With Elotuzumab-Based Treatment. *Cureus*. 2023;15:e49307.
 39. Kikuchi T, Tsukada N, Nomura M, Kasuya Y, Oda Y, Sato K, Takei T, Ogura M, Abe Y, Suzuki K, Ishida T. Real-world clinical outcomes in patients with multiple myeloma treated with Isatuximab after daratumumab treatment. *Ann Hematol*. 2023;102: 1477-1483.
 40. Abe Y, Sasaki M, Takezako N, Ito S, Suzuki K, Handa H, Chou T, Yoshida T, Mori I, Shinozaki T, Suzuki K. Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory

Multiple Myeloma. *Ann Hematol.* 2023;102:2493-2504.

41. Shibayama H, Itagaki M, Handa H, Yokoyama A, Saito A, Kosugi S, Ota S, Yoshimitsu M, Tanaka Y, Kurahashi S, Fuchida SI, Iino M, Shimizu T, Moriuchi Y, Toyama K, Mitani K, Tsukune Y, Kada A, Tamura H, Abe M, Iwasaki H, Kuroda J, Takamatsu H, Sunami K, Kizaki M, Ishida T, Saito T, Matsumura I, Akashi K, Iida S. Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021). *Int J Hematol.* 2024 ;119:707-721.
42. Iida S, Ito S, Yokoyama H, Ishida T, Nagai Y, Handa H, Ito S, Kamei Y, Nakamura M, Suzuki K. Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3. *Jpn J Clin Oncol.* 2024;54:991.
43. Kogure Y, Handa H, Ito Y, Ri M, Horigome Y, Iino M, Harazaki Y, Kobayashi T, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, Shinozaki T, Yoshida T, Mori I, Iida S, Maeda T, Kataoka K. ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone. *Blood.* 2024 ;143:2401-2413.
44. Abe Y, Kubonishi S, Ri M, Iino M, Sunami K, Ito T, Fukaya M, Kitano T, Ikeda S, Ota S, Kuroi T, Iriyama N, Jo T, Adachi M, Ahahane D, Kai T, Kohara Y, Kadowaki N, Katayama T. An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study). *Future Oncol.* 2024;20:1191-1205.
45. Horigome Y, Iino M, Harazaki Y, Kobayashi T, Handa H, Hiramatsu Y, Kuroi T, Tanimoto K, Matsue K, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, Maeda T, Yoshida T, Mori I, Shinozaki T, Iida S. A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan. *Ann Hematol.* 2024;103:475-488.
46. Bar N, Diels J, van Sanden S, Mendes J, Hemando T, Burnett H, Cost P, Schechter JM, Lendvai N, Patel N, Ishida T, Er J, Harrison SJ, Lopez-Munoz N. Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison. *Curr Med Res Opin.* 2024;40:1597-1603.
47. Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hajek R, Liu Z, Minari J, Moreau P, Romejko-Jarosinska J, Spicka I, Vorobyev VI, Besemer B, Ishida T,

- Janowski W, Kalayoglu-Besisik S, Parmar G, Robak P, Zamagni E, Goldschmidt H, Martin TG, Manier S, Mohty M, Oprea C, Bregeault MF, Mace S, Berthou C, Bregman D, Kippel Z, Orlowski RZ, IMROZ Study Group. *N Engl J Med*. 2024;391:1597-1609.
48. Iida S, Ito S, Yokoyama H, Ishida T, Nagai Y, Handa H, Ito S, Kamei Y, Nakamura M, Suzuki K. Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3. *Jpn J Clin Oncol*. 2024;54:991-1000.
 49. Kikuchi T, Tsukada N, Kunisada K Yogo M, Oda Y, Sato K, Takei T, Ogura M, Abe Y, Suzuki K, Ishida T. Prognostic value of the second revision of the international staging system (R2-ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. *Hematol Oncol*. 2024;42:e3248.
 50. Araki M, Mitsuhashi T, Yatabe Y, Arai T, Yokota H, Okita H, Sakurai M, Tsukada N, Kataoka K, Matsushita H. Simple flow cytometry method using a myeloma panel that easily reveals clonal proliferation of mature B-cells. *Clin Chem Lab Med*. 2024 Aug 5. doi: 10.1515/ccm-2024-0359. Online ahead of print.
 51. Kikuchi T, Tsukada N, Kunisada K, Matsumoto C, Nomura-Yogo M, Oda Y, Sato K, Takei T, Ogura M, Abe Y, Suzuki K, Hosoya O, Ishida T. Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real-world clinical setting. *Hematol Oncol*. 2024;42:e3306.
 52. Kikuchi T, Tsukada N, Kunisada K, Matsumoto C, Nomura-Yogo M, Oda Y, Sato K, Takei T, Ogura M, Abe Y, Suzuki K, Hosoya O, Ishida, T. Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting. *Ann Hematol*. 2024;103: 3811-3813.
 53. Kikuchi T, Tsukada N, Kunisada K, Nomura-Yogo M, Oda Y, Sato K, Takei T, Ogura M, Abe Y, Suzuki K, Ishida T. Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma. *Int J Hematol*. 2024;120:91-95.
 54. Kikuchi T, Kunisada K, Sato K, Tsukada N, Ishida T. Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a patient With Multiple Myeloma Treated with Elranatamab. *Cureus*. 2024;16:e74902.
 55. Kikuchi T, Oda Y, Kondo U, Tsukada N, Kunisada K, Matsumoto C, Nomura-Yogo M, Sato K, Takei T, Ogura M, Abe Y, Suzuki K, Hosoya O, Ishida T. Prognostic value of the “dynamic” R2-ISS in patients with multiple myeloma undergoing anti-CD38

- antibody-based triplet therapies. *Hematol Oncol.* 2024;42:e3302.
56. Kikuchi T, Tsukada N, Kunisada K, Nomura-Yogo M, Ishida T. Local Cytokine Release Syndrome After Idecabtagene Vicleucel Therapy in Patients With Multiple Myeloma. Two Case Reports. *Cureus.* 2024;16:e72364.
57. Quach H, Parmar G, Ocio EM, Prince HM, Oriol A, Crowther H, Tsukada N, Bories P, Madan S, Nathwani N, Sunami K, Semiond D, Yu D, Cordero P, Mace S, Suzan F, Moreau P. A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. *Haematologica.* 2024;109:4078-4082.
58. Shimazu Y, Kanda J, Suzuki K, Wada A, Kikuchi T, Ikeda T, Tsukada N, Miwa A, Itagaki M, Kako S, Nishiwaki K, Ota S, Fujiwara SI, Kataoka K, Doki N, Sawa M, Hiramoto N, Nishikawa A, Imai T, Ichinohe T, Kanda Y, Atsuta Y, Kawamura K. The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation. *Cancer Sci.* 2024;115: 2384-2395.
59. Shimizu H, Kato J, Tanoue S, Kimura SI, Tachibana T, Hatano K, Usuki K, Taguchi J, Hagihara M, Tsukada N, Harada K, Takahashi S, Takada S, Sakaida E, Fujisawa S, Onoda M, Aotsuka N, Handa H, Hatta Y, Nakaseko R, Yano S, Ohashi K, Kanda Y, Kanto Study Group for Cell, Therapy. Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols. *Leuk Res.* 2024 Sep;144:107562. doi: 10.1016/j.leukres.2024.107562. Epub 2024 Aug 20.
60. Ishida T, Kuroda Y, Matsue K, Komeno T, Ishiguro T, Ishikawa J, Ito T, Kosugi H, Sunami K, Nishikawa K, Shibayama K, Aida K, Yamazaki H, Inagaki M, Kobayashi H, Iida S. A Phase 1/2 study of teclistamab, a humanized BCMA $\times$ CD3 bispecific Ab in Japanese patients with relapsed/refractory MM. *Int J Hematol.* 2024 Nov 28. doi: 10.1007/s12185-024-03884-z. Epub ahead of print. PMID: 39607603.
61. Kikuchi T, Watanabe M, Tsukada N, Matsumoto C, Nomura-Yogo M, Kunisada K, Sawada H, Sato K, Takei T, Ogura M, Abe Y, Suzuki K, Hosoya O, Ishida T. Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma. *Transplant Infect Dis.* 2025. Apr 21:e70040. doi: 10.1111/tid.70040. Online ahead of print.
62. Kikuchi T, Tsukada N, Kunisada K, Nomura-Yogo M, Oda Y, Sato K, Takei T, Ogura M, Abe Y, Suzuki K, Ishida T. Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma. *Acta Haematol.* 2025;148:85-90.
63. Ailawadhi S, Spicka I, Spencer A, Lu J, Oriol A, Ling S, Schjesvold F, Berkovits A, Hus M, Li C, Dimopoulos MA, Rajnics P, Besisik S, Hungria V, Custidiano MD,

- Parmar G, Leleu X, Li F, Cerchione C, Gomez C, Ishida T, Mateos MV, Buck TT, LeBlanc R, Minarik J, Goldschmidt H, Zhang R, Semiond D, Suzan F, Stefanova-Urena M, Koch V, Moreau P. Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study. *J Clin Oncol*. 2025 Jun 3:JCO2500744. doi: 10.1200/JCO-25-00744. Online ahead of print.
64. Goto H, Sawa M, Fujiwara SI, Ri M, Ishida T, Takeuchi M, Ishitsuka K, Toyosaki M, Sunami K, Tsukada J, Shimogomi A, Ishihashi Y, Ouchi Y, Miyamoot T, Hino M, Maeda Y, Teshima T. Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma. *Sci Rep*. 2025;15:14523.
65. Chen W, Cai Z, Chim JC, Chng WJ, Du J, Fu C, Hanamura I, Hou J, Huang JS, Ishida T, Liu A, Ptushkin V, Semenova A, Takezako N, Wong RSM. Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group. *Clin Hematol Int*. 2025;7:1-19.
66. Yoroidaka T, Takamatsu H, Urushihara R, Itagaki M, Yoshihara S, Sato K, Takezako N, Ozaki S, Suzuki K, Kohno K, Muta T, Matsumoto M, Terasaki Y, Yamashida T, Fuchida S, Sakamoto J, Ishida T, Suzuki K, Murakami H, Durie BGM, Shimizu K. Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study. *Haematologica*. 2025 Apr 17. doi: 10.3324/haematol.2025.287411. Online ahead of print.
67. Kikuchi T, Kondo U, Sugita S, Watanabe M, Matsumoto C, Nomura-Yogo M, Kunisada K, Sawada H, Sato K, Takei T, Ogura M, Abe Y, Hosoya O, Ishida T, Tsukada N. Can baseline Cytomegalovirus IgG titers predict Cytomegalovirus reactivation after ide-cel therapy? *Blood Adv*. 2025 Jul 17:bloodadvances.2025017174. doi: 10.1182/bloodadvances.2025017174. Online ahead of print.
68. Iida S, Sunami K, Ito S, Yuda J, Fujikawa E, Takamoto M, Aida K, Yamazaki H, Takahashi M, Ishida T. Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM. *Int J Hematol*. 2025 May 9. doi: 10.1007/s12185-025-03991-5. Epub ahead of print. PMID: 40343678.

和文原著（2023 年以降）

1. 石田禎夫, 多発性骨髄腫の将来の治療戦略. 日本臨床 2023 ; 81(6) : 800-805.
2. 塚田信弘, 新規治療時代 of 移植医療. 日本臨床 2023 ; 81(6) : 893-898.
3. 石田禎夫, 再発・難治性多発性骨髄腫に対する BCMA-CAR-T 細胞療法 of 長期フォローアップデータ. 血液内科. 2023 ; 86(6) : 862-866
4. 塚田信弘, 多発性骨髄腫に対する二重特異性抗体の開発状況と今後の展望. 血液内科. 2023 ; 87(4) : 472-432.
5. 塚田信弘, 小田祐貴, 野村萌, 粕谷悠, 武井智美, 佐藤広太, 小倉瑞生, 菊池拓, 阿部有, 鈴木憲史, 石田禎夫 : 三剤併用寛解導入療法後に up-front の自家末梢血幹細胞移植を行った多発性骨髄腫 124 例 of リアルワールド解析. 臨床血液. 2023 ; 64 : 1397-1403.
6. 塚田信弘, 移植適応多発性骨髄腫 of 治療戦略 — 現状と将来展望 —. 臨床血液. 2023. 64(9) : 1066-1073.
7. 石田禎夫, 多発性骨髄腫における CAR-T 細胞療法. 日本造血・免疫細胞療法学会雑誌. 2023 ; 12(3) : 141-147.
8. 石田禎夫, 多発性骨髄腫に対する CAR-T 細胞療法 of 現状と課題. 医学 of あゆみ. 2024 ; 288(3) : 193-198.
9. 塚田信弘, 余語萌, 國定浩大, 小田祐貴, 武井智美, 佐藤広太, 小倉瑞生, 菊池拓, 阿部有, 鈴木憲史, 石田禎夫 : TBI 8Gy を含む骨髄破壊的前処置で同種移植を行った多発性骨髄腫 of 後方視的解析. 臨床血液. 2024 ; 65 : 615-621.
10. 塚田信弘, 多発性骨髄腫および類縁疾患に対する自家移植 of 役割. 日本造血・免疫細胞療法学会雑誌. 2025 ; 14(1) : 12-20.